Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug - Legend Biotech (NASDAQ:LEGN)

Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million, 

Related Keywords

Mitchell Kapoor ,Raghuram Selvaraju ,Legend Biotech Corporation ,Biologics License Application ,